Randomized Phase II Trial of Ipilimumab (study drug) with or without Bevacizumab (study drug) in Patients with Unresectable Stage III or Stage IV Melanoma
Cancer - Melanoma
John McCann, MD
D’Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
Baystate Franklin Medical Center
64 High Street
The purpose of this study is to compare overall survival for patients with stage III or stage IV melanoma who receive ipilimumab plus bevacizumab versus ipilimumab alone.
Patients with unresectable Stage III or Stage IV Melanoma; untreated or one previous treatment.